Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 3/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | WNT3 | P56703 | 1/20 | 0.31 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299461 | 0.90 | LMNA (0.34) | LMNAPKMTACR1NPC1CACNA1B | |
| SCHEMBL4300130 | 0.89 | LMNA (0.33) | LMNAPKMTACR1NPC1CACNA1B | |
| SCHEMBL4303618 | 0.86 | WNT3 (0.34) | LMNATACR1POLBWNT3SFRP1 | |
| SCHEMBL4302525 | 0.86 | NPC1 (0.39) | LMNANPC1 | |
| SCHEMBL4294660 | 0.85 | NPC1 (0.33) | RORCNPC1AKT1L3MBTL1 | |
| SCHEMBL3406629 | 0.84 | LMNA (0.36) | LMNAPKMRORCNPC1POLB | |
| SCHEMBL4293128 | 0.81 | NPC1 (0.34) | RORCNPC1CACNA1BPOLB | |
| SCHEMBL700983 | 0.80 | LMNA (0.34) | LMNAPKMTACR1NPC1CACNA1B | |
| SCHEMBL701062 | 0.80 | TACR1 (0.34) | LMNAPKMTACR1NPC1CACNA1B | |
| SCHEMBL4296232 | 0.77 | HTR7 (0.38) | WNT3SFRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | claimed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264400-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | LMNA 2572/4885PKM 910/4885RORC 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.